-
Recent Posts
- Timeless Good Advice? (Action for Happiness)
- The Diversionary Value of Music Playlists for Patients With Dementia in Accident and Emergency Settings (Nurses.co.uk / BBC News)
- More on the Possible Role of Neuroinflammation in Frontotemporal Dementia (Bazian / Brain)
- COVID-19 Infection: Coronavirus in the UK (DHSC / PHE / BBC News / SCIE / NHS England)
- Interventions to Improve Resilience in People Living With Dementia (Frontiers in Medicine)
Archives
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Cerebrospinal Fluid (CSF) Biomarkers
Transcranial Electromagnetic Treatment in Alzheimer’s Disease: Early Promising Results? (JAD / Bazian)
Summary Transcranial Electromagnetic Treatment (TEMT) for persons with mild / moderate Alzheimer’s Disease, delivered ia a bathing cap-style head device called the MemorEM, appears to bring about various statistically significant improvements without any observable adverse effects. Benefits are said to include: “ …cognitive enhancement, changes to CSF / … Continue reading →
Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, NHS Digital (Previously NHS Choices), Non-Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged 2DG-PET, ADAS-Cog: Alzheimer’s Disease Assessment Scale - Cognitive Subscale, Adverse Event Assessment, Aβ Accumulation, Aβ-Plaques, Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog), Alzheimer’s Disease Biomarkers, Alzheimer’s Disease Cooperative Study - Activities of Daily Living, Angel Investor Forum, Bazian, Behind the Headlines, Blood Proteins as Biomarkers of Disease Research, Blood-Based Biomarkers, Byrd Alzheimer's Institute (Tampa Florida), Cerebral Metabolic Rate for Glucose (Via 2DG-PET), Cerebrospinal Fluid (CSF), Cerebrospinal Fluid (CSF) Biomarkers, Clock Drawing Test, College of Pharmacy: University of South Florida, Critical Appraisals, CSF Biomarkers, Czech Republic, Department of Neurology: Charles University (Prague), Diffusion Tensor Imaging (DTI), Digit Span, FDG-PET Imaging, fMRI, Functional Magnetic Resonance Imaging (fMRI), Glass Charitable Foundation, Invicro (Boston USA), Journal of Alzheimer's Disease, Journal of Alzheimer’s Disease (JAD), Left Coast Engineering (Escondido California), MemorEM (Transcranial Electromagnetic Stimulation), Motol University Hospital (Prague), MRI Scans, National Institute of Neurological Disorders and Stroke (NINDS), NeuroEM Therapeutics Inc. (Phoenix Arizona), Ocotillo Electromagnetics Inc. (Chandler Arizona), olumbia Suicide Severity Rating Scale, Plasma Biomarkers, Rey Auditory Verbal Learning Test (Rey AVLT), Rey AVLT, RF Exposure Laboratory (San Marcos California), School of Aging Studies: University of South Florida, Transcranial Brain Stimulation, Transcranial Electromagnetic Treatment (TEMT), United States, University Diagnostic Institute (Tampa Florida), University of South Florida, University of South Florida Health / Byrd Alzheimer's Institute, USA
|
Leave a comment
Dementia Biomarkers Re-Explored? (General Psychiatry / JGCR)
Summary A recent systematic review examines biomarkers, as strictly defined, for neurodegenerative diseases. “Vast improvements in neuroimaging techniques have led to newly discovered biomarkers and diagnostics”. p.5 Behavioural biomarkers are mentioned hardly at all. Full Text Link Reference Maclin, JMA. … Continue reading →
Posted in Alzheimer’s Research UK, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Mental Health, Personalisation, Quick Insights, Systematic Reviews, UK, Universal Interest
|
Tagged 18F-florbetaben, 18F-flutemetamol, 18Fflorbetapir, Alzheimer's Disease: Diagnosis, Alzheimer’s Disease, Alzheimer’s Disease and Dementia, Alzheimer’s Disease Biomarkers, Alzheimer’s Research UK (ARUK), Amyloid and Tau PET, APOE e4 (Apolipoprotein E e4), Apolipoprotein E (APOE) e4 Allele, Behavioural Biomarkers, Beta-Amyloid PET Imaging, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Canonical Syndromes of Primary Progressive Aphasia: Non-Fluent / Agrammatic Variant (nfvPPA), Canonical Syndromes of Primary Progressive Aphasia: Semantic Variant (svPPA), Carbon-11 Pittsburgh Compound-B (C-PIB) Radioisotope Tracer, Cerebral Metabolic Rate for Glucose (CMRgl), Cerebrospinal Fluid (CSF) Biomarkers, Cerebrospinal Fluid and Serum MHPG, CMRgl Decline, Corticobasal Degeneration (CBD), CSF 3-methoxy-4-hydrox-yphenylglycol (MHPG), Dementia With Lewy Bodies (DLB), Differential Diagnosis, DLB: Dementia with Lewy Bodies, Docosahexaenoic Acid (DHA), Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Eicosapentaenoic Acid (EPA), Frontotemporal Dementia (FTD), α-Synuclein, Journal of Geriatric Care and Research (JGCR), Lewy Body Dementia (LBD), Magnetic Resonance Imaging (MRI), Medial Temporal Lobe Atrophy (MTA), Medial Temporal Lobes (MTL), Metabolic Syndrome (MetS), MRI Brain Imaging, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neuroimaging, Neuroimaging in Dementia Diagnosis, Non-Invasive Biomarkers, Pick’s Disease (Frontotemporal Dementia), Positron Emission Tomography (PET), Preclinical Alzheimer's Disease, Primary Progressive Aphasia (PPA), Progressive Supranuclear Palsy (PSP), Rapid Screening, Screening for Dementia, Sea Hero Quest (SHQ) Game, Sea Hero Quest VR, Tau PET, Timely Diagnosis, VaD: Vascular Dementia, Variants of Primary Progressive Aphasia (PPA), Vascular Dementia, [18F]THK5351
|
Leave a comment
Earlier Diagnosis Research: the Deep and Frequent Phenotyping Study (BBC News / GtR)
Summary The Deep and Frequent Phenotyping Study aims to discover new ways of diagnosing dementia, ideally decades before the symptoms become apparent in order to give future drug treatments the best chance of working. The Deep and Frequent Phenotyping Study … Continue reading →
Posted in Alzheimer's Society, BBC News, Commissioning, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Mental Health, Models of Dementia Care, National, NIHR, Quick Insights, UK, Universal Interest
|
Tagged Ageing Population, Alterations in Movement and Walking (“Gait”) Assessments, Alzheimer's Disease: Early Detection by Brain Scan, Alzheimer’s Disease Biomarkers, Amnestic Mild Cognitive Impairment (a-MCI), Amnestic Mild Cognitive Impairment (aMCI), Applications of Big Data, BBC Radio, BBC Radio 4, BBC's World At One Programme, Big Data Analytics, Big Data Funding and Research, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Biomarkers Research Programmes, Blood and Urine Biomarkers, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Scans, Cambridge Neuropsychological Test Automated Battery (CANTAB), Cerebrospinal Fluid (CSF) Biomarkers, Clinical Assessments, Cognitive Assessments / Screening Tools, Conversion to Dementia From Prodromal Disease, CSF Biomarkers, Deep and Frequent Phenotyping Study, Deep and Frequent Phenotyping Study (DFP), Deep and Frequent Phenotyping; Combinatorial Biomarkers of Dementia, Dementia Research, Dementia Research Funding, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, DFP Study Team, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DPUK: Dementias Platform UK, Drug Trials Failure Rate, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, EEG: Electroencephalography, Effectiveness of Early Detection and Treatment, Electroencephalogram (EEG) Brain Scans, Electroencephalography (EEG), Gait and Cognition, Gait Changes, Gateway to Research (GtR), Global Dementia Research, Global Leadership, Hypothetical Prodromes of Dementia, Imanova, Imperial College London, Join Dementia Research, Join Dementia Research: Clinical Trials Matchmaker Service, Join Dementia Research: Recruitment Onto Dementia Studies, Kings College London, Magnetic Resonance Imaging (MRI) Scan, Magnetoencephalography (MEG), Medical Research Council (MRC), Medical Research Council (UK), National Institute of Health Research (NIHR), Neurobiology of Aging (Journal), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Newcastle University, Non-Invasive Biomarkers, Ocular Manifestations in Neurodegenerative Diseases, Open Data and Big Data, Ophthalmological Assessments, Participation in Research, Participation in Research Studies, Partnership and Collaboration, Patient and Public Participation, PharmaCog Consortium, Positron Emission Tomography (PET), Pre-Clinical Genotype-Phenotype Predictors of Alzheimer's Disease, Prodromal Alzheimer's Disease, Professor Clare Mackay: Imaging Neuroscience at the University of Oxford, Professor Lynn Rochester: Clinical Ageing Research Unit at Newcastle University, Professor Simon Lovestone: Lead Researcher and Professor of Translational Neuroscience at University of Oxford, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Proteomic Analysis, Proteomics, Public Participation in Research, Publicly-Funded UK Big Data Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Funding, Retina as Early Biomarker of Neurodegeneration, Retinal Biomarkers, Retinal Changes as Surrogate Biomarker for Alzheimer's Disease, Retinal Ganglion Cells (RGCs), Retinal Manifestations of Alzheimer's Disease, Screening Tools for Amnestic Mild Cognitive Impairment (a-MCI), Surrogate Biomarkers of Neurodegeneration, Translational Research, University College London, University of Cambridge, University of Edinburgh, University of Manchester, University of Oxford, Volunteers, Walking Pattern (Gait), Wearable Devices, Wearables (Technology)
|
Leave a comment
Early Promising Signs in Verubecestat Human Drug Trial – Since Dashed (NHS Choices / Science Translational Medicine / Translational Neurodegeneration / Biospace Inc)
Summary Early results from a Phase I trial indicate that the BACE1 inhibitor Verubecestat may effectively reduce β-amyloid formation in human patients with Alzheimer’s Disease. This appears to confirm previous trials with rats, monkeys and healthy young human adults. As … Continue reading →
Posted in Animal Studies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Aducanumab, Aducanumab (Biogen), Aβ40, Aβ42, Amyloid, Amyloid Beta, Amyloid Hypothesis, Amyloid Precursor Protein (APP), Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Amyloidopathy, Anti-Amyloid Therapies, APECS Phase 3 Trial (ClinicalTrials.gov Identifier: NCT01953601), Aspartyl Proteases β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1 or β-Secretase), ß-amyloid, BACE1, BACE1 Inhibitors, Behind the Headlines, Beta-Amyloid, Beta-Amyloid Plaques, Biomarkers, Cerebrospinal Fluid (CSF), Cerebrospinal Fluid (CSF) Biomarkers, Cleveland Clinic Foundation, Department of Biostatistics: Merck Research Laboratories, Department of Clinical Research: Merck Research Laboratories, Department of Global Chemistry: Merck Research Laboratories, Department of Neuroscience: Merck Research Laboratories, Department of Pharmacokinetics Pharmacodynamics and Drug Metabolism: Merck Research Laboratories, Department of Safety Assessment: Merck Research Laboratories, Department of Translational Medicine: Merck Research Laboratories, EPOCH Phase 2/3 Trial (ClinicalTrials.gov Identifier: NCT01739348), β-Secretase 1 (BACE1), Lerner Research Institute, Merck Research Laboratories, PAREXEL (Glendale USA), Phase III APECS Study, sAPPβ, Science Translational Medicine, Translational Biomarkers Department: Merck Research Laboratories, Translational Neurodegeneration, United States, USA, Verubecestat, Verubecestat: Reduction of CSF Aβ and sAPPβ in Healthy Adults and AD Patients
|
Leave a comment
Deep and Frequent Phenotyping Study: Dementia Early Detection and Biomarkers Research Programme (MRC / NIHR)
Summary The Deep and Frequent Phenotyping Study will explore improvements in biomarker research and the development of tests to detect Alzheimer’s Disease early on. This research programme will be funded by the National Institute of Health Research (NIHR) and the … Continue reading →
Posted in Alzheimer's Society, Charitable Bodies, Commissioning, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, National, NIHR, Quick Insights, UK, Universal Interest
|
Tagged Alterations in Movement and Walking (“Gait”) Assessments, Alzheimer's Disease: Early Detection by Brain Scan, Alzheimer’s Disease Biomarkers, Aridhia, AstraZeneca / MedImmune, Berry Consultants, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Biomarkers Research Programmes, Blood and Urine Biomarkers, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Scans, Cambridge Cognition, Cerebrospinal Fluid (CSF) Biomarkers, Clinical Assessments, Cognitive Assessments / Screening Tools, Conversion to Dementia From Prodromal Disease, CSF Biomarkers, Deep and Frequent Phenotyping Study, Dementia Research, Dementia Research Funding, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DPUK: Dementias Platform UK, Dr Rob Buckle: Director of Science Programmes at MRC, Drug Trials Failure Rate, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, EEG: Electroencephalography, Effectiveness of Early Detection and Treatment, Electroencephalogram (EEG) Brain Scans, Electroencephalography (EEG), Exprodo, Gait and Cognition, Gait Changes, Global Dementia Research, Global Leadership, Hypothetical Prodromes of Dementia, Imanova, Imperial College London, IXICO, Kings College London, Magnetic Resonance Imaging (MRI) Scan, Magnetoencephalography (MEG), Medical Research Council (MRC), Medical Research Council (UK), National Institute of Health Research (NIHR), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Newcastle University, Non-Invasive Biomarkers, Ocular Manifestations in Neurodegenerative Diseases, Ophthalmological Assessments, Optos, Participation in Research, Participation in Research Studies, Partnership and Collaboration, Patient and Public Participation, Positron Emission Tomography (PET), Pre-Clinical Genotype-Phenotype Predictors of Alzheimer's Disease, Prodromal Alzheimer's Disease, Professor Chris Whitty: Chief Scientific Adviser at Department of Health, Professor Simon Lovestone: Lead Researcher and Professor of Translational Neuroscience at University of Oxford, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Proteomic Analysis, Proteomics, Public Participation in Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Funding, Retina as Early Biomarker of Neurodegeneration, Retinal Biomarkers, Retinal Changes as Surrogate Biomarker for Alzheimer's Disease, Retinal Ganglion Cells (RGCs), Retinal Manifestations of Alzheimer's Disease, Sage Bionetworks, Surrogate Biomarkers of Neurodegeneration, Translational Research, TrialSpark, University College London, University of Cambridge, University of Edinburgh, University of Manchester, University of Oxford, Volunteers, Walking Pattern (Gait), Wearable Devices, Wearables (Technology), West London Mental Health Trust / Imperial College London
|
1 Comment
Diagnosis, Screening, Assessment and Symptoms-Related Systematic Reviews and Meta-Analyses
Recent reviews and meta-analyses on the broad topics diagnosis, screening and assessment are listed below. Some of these articles may be available freely (according to local circumstances). A suitable Athens password, a journal subscription or payment for access may be … Continue reading →
Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Models of Dementia Care, Systematic Reviews
|
Tagged Addenbrooke's Cognitive Examination (ACE), Addenbrooke's Cognitive Examination-Revised (ACE-R), Assessment and Diagnosis, Biomarkers, Blood-Based Biomarkers, Breaking Bad News, Case Identification and Screening, Cerebrospinal Fluid (CSF) Biomarkers, Cognitive Screening, CSF Biomarkers, Dementia Diagnosis, Dementia Screening, Diagnosis and Assessment, Diagnosis and Referral, Diagnosis and Support, Differential Diagnosis, Disclosure of Diagnosis, fMRI, Functional Magnetic Resonance Imaging (fMRI), Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), Plasma Biomarkers, Screening, Screening for Cognitive Impairment, Screening for Dementia, Systematic Review of Screening for Dementia in the Older Population
|
Leave a comment
Concerning the Diagnostic Accuracy of Plasma and CSF Biomarkers (Cochrane Database)
Summary This systematic review investigates the diagnostic accuracy of blood plasma and CSF Aß levels for detecting patients with mild cognitive impairment (MCI) and who are likely to progress to Alzheimer’s Disease or other types of dementia. The accuracy of … Continue reading →
Posted in Charitable Bodies, Diagnosis, For Doctors (mostly), For Researchers (mostly), International, Systematic Reviews, UK
|
Tagged Aß40, Aß42, ALOIS: the Cochrane Dementia and Cognitive Improvement Group, Alzheimer's Association, Alzheimer's Disease and Related Disorders Association (Now the Alzheimer's Association), Alzheimer’s Disease Biomarkers, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Apolipoprotein E, Asymptomatic Alzheimer’s Disease, Beta-Amyloid, Beta-Amyloid Plaques, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood-Based Biomarkers, Cambridge Institute of Public Health, Cambridge Institute of Public Health: Cambridge University, Candidate Blood Proteome Markers, Cerebrospinal Fluid, Cerebrospinal Fluid (CSF), Cerebrospinal Fluid (CSF) Biomarkers, Cochrane Database, Cochrane Database of Systematic Reviews, Cochrane Dementia and Cognitive Improvement Group, Cochrane Register of Diagnostic Test Accuracy Studies, Cognitive Impairment, Cognitive Response to Progression of Pathophysiology, Conversion to Dementia From Prodromal Disease, CSF Aß Levels, CSF Aβ, CSF Biomarkers, CSF Tau, Dementia Screening, Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV), Diagnostic Test Accuracy, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Differential Diagnosis, Early Screening, Fluid and Imaging Biomarkers, Imperial College London, Institute of Public Health: University of Cambridge, β-amyloid, β-Amyloid 1-42 (Aβ42), MCI: Mild Cognitive Impairment, Mild Cognitive Impairment (MCI), National Institute of Neurological and Communicative Disorders and Stroke, Neurodegeneration, NINCDS-ADRDA Criteria, NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association, Plasma Biomarkers, Plasma Proteins, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Progression of Mild Cognitive Impairment to Dementia, Systematic Reviews and Meta-Analyses, Transition from Cognitive Impairment to Dementia, University of Birmingham, University of Cambridge, University of Oxford, University of Oxford: Radcliffe Department of Medicine, University of Western Australia, US Alzheimer's Association, Western Australian Centre for Health and Ageing (WACHA)
|
Leave a comment
